New Delhi, Sept. 26 -- US President Donald Trump's latest tariff missile imposing a 100% levy on branded or patented pharmaceuticals is unlikely to have much impact on India's drug industry that mostly ships generic or off-patent medicines to the US, said government officials and industry experts.

Two government officials said New Delhi is examining the impact of Trump's decision on generic drugs exported by India to the US.

"We [India's pharmaceutical industry] are largely into generic drug exports. Given their price competitiveness, we will continue to export to the US regularly, as [the generic drugs] are still expected to remain outside the scope of the new reciprocal tariff regime," one of them said.

"We are examining the proposal...